Compare
Natera, Inc. vs Guardant Health, Inc. vs Caris Life Sciences, Inc. vs Veracyte, Inc.
| Latest fiscal year | Natera, Inc. NTRA | Guardant Health, Inc. GH | Caris Life Sciences, Inc. CAI | Veracyte, Inc. VCYT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.31B | $982.02M | $812.03M | $517.14M |
| Revenue growth (YoY) | +35.9% | +32.9% | +97.0% | +16.0% |
| Gross margin | n/a | 64.5% (computed) | n/a | 70.1% |
| Operating margin | -13.4% | -44.5% | 5.6% | 11.2% |
| Net margin | -9.0% | -42.4% | -8.4% | 12.8% |
| Net income | -$208.16M | -$416.28M | -$68.09M | $66.35M |
| EPS (Diluted) | -$1.52 | -$3.32 | -$3.22 | $0.82 |
| Operating cash flow | $215.30M | -$184.76M | $83.16M | $136.31M |
| Free cash flow | $109.11M | -$233.07M | $66.89M | $126.63M |
| Cash & equivalents | n/a | $378.20M | $796.27M | $362.58M |
| Total assets | $2.40B | $2.01B | $1.13B | $1.41B |
| Total liabilities | $685.93M | $2.11B | $548.36M | $96.44M |
| Shareholders' equity | $1.71B | -$99.31M | $577.31M | $1.31B |
| Return on year-end equity | -12.2% | n/a | -11.8% | 5.1% |
| Shares outstanding | 139.69M | 130.64M | 282.53M | 79.36M |
Revenue, most recent five fiscal years
| Fiscal year | Natera, Inc. | Guardant Health, Inc. | Caris Life Sciences, Inc. | Veracyte, Inc. |
|---|---|---|---|---|
| Latest | $2.31B Ended 2025-12-31 | $982.02M Ended 2025-12-31 | $812.03M Ended 2025-12-31 | $517.14M Ended 2025-12-31 |
| 1 year earlier | $1.70B Ended 2024-12-31 | $739.02M Ended 2024-12-31 | $412.26M Ended 2024-12-31 | $445.76M Ended 2024-12-31 |
| 2 years earlier | $1.08B Ended 2023-12-31 | $563.95M Ended 2023-12-31 | $306.13M Ended 2023-12-31 | $361.05M Ended 2023-12-31 |
| 3 years earlier | $820.22M Ended 2022-12-31 | $449.54M Ended 2022-12-31 | n/a | $296.54M Ended 2022-12-31 |
| 4 years earlier | $625.49M Ended 2021-12-31 | $373.65M Ended 2021-12-31 | n/a | $219.51M Ended 2021-12-31 |